New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera
Polycythemia vera (PV) is a cancer originating from a disease-initiating [...]
HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
Liang Schweizer, PhD, Founder, CEO, and Chairperson of HiFiBiO Therapeutics, [...]
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government Contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
“We are pleased to accept this award and collaboration with [...]
Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections
Greg Merril, co-Founder and CEO of Adaptive Phage Therapeutics: “This [...]
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
“With the option for subcutaneous self-administration, crovalimab could help meet [...]
DxVx, Won the Governmental Project to Develop Diagnostic Sensor Kit for Adult Diseases
In this project, which will be carried out over three [...]
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
“At ASCO, we are reporting early clinical data for three [...]
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
The company updated the Phase 1b efficacy and safety results [...]
Pangaea Data Awarded Strategic Partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC)
Dr. Vibhor Gupta, Founder and Director at Pangaea, said: “We [...]
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
Omeros received approximately $126 million in cash at closing. In [...]